KROS
Price
$11.08Alerts
Change
-$0.31 (-2.72%)
Updated
Nov 20 closing price
Capitalization
185.58M
102 days until earnings call
Intraday BUY SELL Signals
LQDA
Price
$54.43Alerts
Change
-$2.20 (-3.88%)
Updated
Nov 20 closing price
Capitalization
3.97B
117 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

KROS vs LQDA

KROS vs LQDA Comparison Chart in %
View a ticker or compare two or three
VS
KROS vs. LQDA commentary
Nov 21, 2026

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is KROS is a Hold and LQDA is a Hold.

Interact to see
Advertisement
SUMMARIES
A.I.Advisor
a Summary for KROS with price predictions
Nov 20, 2026

KROS in upward trend: price rose above 50-day moving average on November 17, 2026

KROS moved above its 50-day moving average on November 17, 2026 date and that indicates a change from a downward trend to an upward trend. In 39 of 45 similar past instances, the stock price increased further within the following month. The odds of a continued upward trend are 87%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where KROS's RSI Oscillator exited the oversold zone, 29 of 37 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are 78%.

The Momentum Indicator moved above the 0 level on November 17, 2026. You may want to consider a long position or call options on KROS as a result. In 75 of 95 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are 79%.

The Moving Average Convergence Divergence (MACD) for KROS just turned positive on November 17, 2026. Looking at past instances where KROS's MACD turned positive, the stock continued to rise in 31 of 43 cases over the following month. The odds of a continued upward trend are 72%.

Following a +19.64% 3-day Advance, the price is estimated to grow further. Considering data from situations where KROS advanced for three days, in 224 of 294 cases, the price rose further within the following month. The odds of a continued upward trend are 76%.

Bearish Trend Analysis

The Stochastic Oscillator has been in the overbought zone for 2 days. Expect a price pull-back in the near future.

The 10-day moving average for KROS crossed bearishly below the 50-day moving average on November 03, 2026. This indicates that the trend has shifted lower and could be considered a sell signal. In 13 of 17 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are 76%.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where KROS declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 75%.

KROS broke above its upper Bollinger Band on November 18, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

The Aroon Indicator for KROS entered a downward trend on November 16, 2026. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of 26 (best 1 - 100 worst) indicates that the company is slightly undervalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (0.707) is normal, around the industry mean (3.596). P/E Ratio (-2.907) is within average values for comparable stocks, (-1.186). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (9.158). Dividend Yield (0.000) settles around the average of (131.631) among similar stocks. P/S Ratio (19.417) is also within normal values, averaging (443.347).

The Tickeron Price Growth Rating for this company is 56 (best 1 - 100 worst), indicating steady price growth. KROS’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is 95 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron PE Growth Rating for this company is 98 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. KROS’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

A.I.Advisor
a Summary for LQDA with price predictions
Nov 20, 2026

LQDA in upward trend: 10-day moving average crossed above 50-day moving average on November 13, 2026

The 10-day moving average for LQDA crossed bullishly above the 50-day moving average on November 13, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 14 of 16 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 88%.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

The Moving Average Convergence Divergence (MACD) for LQDA just turned positive on October 16, 2026. Looking at past instances where LQDA's MACD turned positive, the stock continued to rise in 46 of 53 cases over the following month. The odds of a continued upward trend are 87%.

LQDA moved above its 50-day moving average on November 10, 2026 date and that indicates a change from a downward trend to an upward trend.

Following a +13.07% 3-day Advance, the price is estimated to grow further. Considering data from situations where LQDA advanced for three days, in 280 of 325 cases, the price rose further within the following month. The odds of a continued upward trend are 86%.

The Aroon Indicator entered an Uptrend today. In 200 of 247 cases where LQDA Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are 81%.

Bearish Trend Analysis

The 10-day RSI Indicator for LQDA moved out of overbought territory on November 20, 2026. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 52 similar instances where the indicator moved out of overbought territory. In 42 of the 52 cases, the stock moved lower in the following days. This puts the odds of a move lower at 81%.

The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 7 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.

Following a 3-day decline, the stock is projected to fall further. Considering past instances where LQDA declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 82%.

LQDA broke above its upper Bollinger Band on November 10, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.

Fundamental Analysis (Ratings)

The Tickeron SMR rating for this company is 12 (best 1 - 100 worst), indicating very strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Price Growth Rating for this company is 36 (best 1 - 100 worst), indicating steady price growth. LQDA’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Profit vs. Risk Rating rating for this company is 49 (best 1 - 100 worst), indicating well-balanced risk and returns. The average Profit vs. Risk Rating rating for the industry is 83, placing this stock slightly better than average.

The Tickeron Valuation Rating of 75 (best 1 - 100 worst) indicates that the company is slightly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (20.369) is normal, around the industry mean (6.379). P/E Ratio (28.101) is within average values for comparable stocks, (0.548). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.202). Dividend Yield (0.000) settles around the average of (0.061) among similar stocks. P/S Ratio (14.286) is also within normal values, averaging (183.387).

The Tickeron PE Growth Rating for this company is 97 (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

FUNDAMENTALS RATINGS
KROS vs LQDA: Fundamental Ratings
KROS
LQDA
OUTLOOK RATING
1..100
3541
VALUATION
overvalued / fair valued / undervalued
1..100
26
Undervalued
75
Overvalued
PROFIT vs RISK RATING
1..100
10049
SMR RATING
1..100
9512
PRICE GROWTH RATING
1..100
5636
P/E GROWTH RATING
1..100
9897
SEASONALITY SCORE
1..100
27n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

KROS's Valuation (26) in the null industry is somewhat better than the same rating for LQDA (75) in the Pharmaceuticals Major industry. This means that KROS’s stock grew somewhat faster than LQDA’s over the last 12 months.

LQDA's Profit vs Risk Rating (49) in the Pharmaceuticals Major industry is somewhat better than the same rating for KROS (100) in the null industry. This means that LQDA’s stock grew somewhat faster than KROS’s over the last 12 months.

LQDA's SMR Rating (12) in the Pharmaceuticals Major industry is significantly better than the same rating for KROS (95) in the null industry. This means that LQDA’s stock grew significantly faster than KROS’s over the last 12 months.

LQDA's Price Growth Rating (36) in the Pharmaceuticals Major industry is in the same range as KROS (56) in the null industry. This means that LQDA’s stock grew similarly to KROS’s over the last 12 months.

LQDA's P/E Growth Rating (97) in the Pharmaceuticals Major industry is in the same range as KROS (98) in the null industry. This means that LQDA’s stock grew similarly to KROS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
KROSLQDA
RSI
ODDS (%)
Bullish Trend 1 day ago
78%
Bearish Trend 1 day ago
81%
Stochastic
ODDS (%)
Bearish Trend 1 day ago
81%
Bearish Trend 1 day ago
82%
Momentum
ODDS (%)
Bullish Trend 1 day ago
79%
N/A
MACD
ODDS (%)
Bullish Trend 1 day ago
72%
Bullish Trend 4 days ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
77%
Bearish Trend 1 day ago
81%
TrendMonth
ODDS (%)
Bearish Trend 1 day ago
77%
Bullish Trend 1 day ago
86%
Advances
ODDS (%)
Bullish Trend 3 days ago
76%
Bullish Trend 9 days ago
86%
Declines
ODDS (%)
Bearish Trend 1 day ago
75%
Bearish Trend 5 days ago
82%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
86%
Bearish Trend 1 day ago
83%
Aroon
ODDS (%)
Bearish Trend 1 day ago
79%
Bullish Trend 1 day ago
81%
COMPARISON
Comparison
Nov 21, 2026
Stock price -- (KROS: $11.08 vs. LQDA: $54.43)
Brand notoriety: KROS and LQDA are both not notable
KROS represents the Biotechnology, while LQDA is part of the Pharmaceuticals: Generic industry
Current volume relative to the 65-day Moving Average: KROS: 99% vs. LQDA: 33%
Market capitalization -- KROS: $185.58M vs. LQDA: $3.97B
KROS [@Biotechnology] is valued at $185.58M. LQDA’s [@Pharmaceuticals: Generic] market capitalization is $3.97B. The market cap for tickers in the [@Biotechnology] industry ranges from $58 to $138.67B. The market cap for tickers in the [@Pharmaceuticals: Generic] industry ranges from $2.12K to $68.49B. The average market capitalization across the [@Biotechnology] industry is $2.24B. The average market capitalization across the [@Pharmaceuticals: Generic] industry is $4.46B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is overvalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

KROS’s FA Score shows that 1 FA rating(s) are green while LQDA’s FA Score has 1 green FA rating(s).

  • KROS’s FA Score: 1 green, 4 red.
  • LQDA’s FA Score: 1 green, 4 red.
According to our system of comparison, LQDA is a better buy in the long-term than KROS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

KROS’s TA Score shows that 5 TA indicator(s) are bullish while LQDA’s TA Score has 5 bullish TA indicator(s).

  • KROS’s TA Score: 5 bullish, 5 bearish.
  • LQDA’s TA Score: 5 bullish, 4 bearish.
According to our system of comparison, LQDA is a better buy in the short-term than KROS.

Price Growth

KROS (@Biotechnology) experienced а +7.57% price change this week, while LQDA (@Pharmaceuticals: Generic) price change was -5.19% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -11.58%. For the same industry, the average monthly price growth was -18.26%, and the average quarterly price growth was -28.15%.

The average weekly price growth across all stocks in the @Pharmaceuticals: Generic industry was -7.72%. For the same industry, the average monthly price growth was -10.88%, and the average quarterly price growth was -13.25%.

Reported Earning Dates

KROS is expected to report earnings on Mar 03, 2027.

LQDA is expected to report earnings on Mar 18, 2027.

Industries' Descriptions

@Biotechnology (-11.58% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

@Pharmaceuticals: Generic (-7.72% weekly)

A generic drug contains the same chemical substance as a drug that was originally protected by patents. Generic drugs are generally sold at cheaper price points, compared to name-brand pharmaceuticals, after patents for the more expensive drugs lapse. The generic drug industry has created a major market, thanks to the lower pricing. According to the Center for Justice and Democracy at New York Law School, 80 percent of all drugs prescribed are generic, and generic drugs are chosen 94 percent of the time when they are available. But their manufacturers must be able to prove to the FDA that they can be effective substitutes for the original drugs. Some of the major generic drug makers include Zoetis, Inc., Allergan plc and Mylan N.V.

View a ticker or compare two or three
Interact to see
Advertisement

KROS and

Correlation & Price change

A.I.dvisor indicates that over the last year, KROS has been loosely correlated with SANA. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if KROS jumps, then SANA could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To KROS
1D Price
Change %
KROS100%
-2.72%
SANA - KROS
47%
Loosely correlated
-8.62%
IMNM - KROS
45%
Loosely correlated
-5.54%
ARVN - KROS
44%
Loosely correlated
-4.15%
TSHA - KROS
44%
Loosely correlated
-1.33%
AXON - KROS
43%
Loosely correlated
-5.16%
More

LQDA and

Correlation & Price change

A.I.dvisor indicates that over the last year, LQDA has been loosely correlated with UNCY. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if LQDA jumps, then UNCY could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To LQDA
1D Price
Change %
LQDA100%
-3.88%
UNCY - LQDA
34%
Loosely correlated
-5.10%
GOSS - LQDA
34%
Loosely correlated
-4.54%
VIR - LQDA
32%
Poorly correlated
-5.41%
KROS - LQDA
32%
Poorly correlated
-2.72%
MNKD - LQDA
32%
Poorly correlated
-2.53%
More
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
HDLB16.010.07
+0.43%
ETRACS Monthly Pay 2xLeveraged US High Dividend Low Volatility ETN Series B (HDLB)
DURA38.93-0.23
-0.59%
VanEck Durable High Dividend ETF (DURA)
DJUL48.56-1.03
-2.07%
FT Vest U.S. Equity Deep Buffer ETF - July (DJUL)
MFEM22.49-1.23
-5.18%
PIMCO RAFI Dynamic Multi-Factor Emerging Markets Equity ETF (MFEM)
ARTY53.94-5.50
-9.25%
iShares Future AI & Tech ETF (ARTY)